Ipsen

Overview

Ipsen is a French biopharmaceutical company specializing in oncology, rare diseases, and neuroscience, with a focused portfolio approach that differentiates it from big pharma diversification.

Historical Timeline

• 1929: Founded as a small French pharmaceutical company
• 1990s: Focuses on endocrinology and oncology specialties
• 2010: Launches Dysport (botulinum toxin) in US market
• 2019: Acquires Clementia Pharmaceuticals for $1.2B (fibrodysplasia drug)
• 2022: Revenue reaches €3.1B; oncology portfolio drives growth
• 2024: Announces major investment in radiopharmaceutical oncology

Business Model

Three therapeutic areas: Oncology (45% — Cabometyx, Onureg), Rare Disease (30% — Dysport, Somatuline), and Neuroscience (25% — Nuplazid). Revenue from prescription drug sales globally, with strong US presence through partnerships and direct sales force.

Moat Analysis

Focused portfolio in high-growth therapeutic areas (oncology, rare diseases) means deeper expertise than diversified competitors. Botulinum toxin franchise (Dysport) competes directly with Allergan's Botox. European headquarters provides advantageous pricing and regulatory environment.

Key Data

• revenue: ~€3.3B (2023)
• market_cap: ~€8B
• r_and_d: ~15% of revenue
• employees: ~6,600
• countries: ~120

Interesting Facts

• Ipsen's Dysport is one of only four botulinum toxin products approved by the FDA — competing directly with Botox in a $6B+ market.
• Despite being much smaller than Big Pharma, Ipsen's oncology revenue per employee exceeds that of several major pharmaceutical companies.